GlassScriptPhysician profile
Monica A Lynn
NPI 1205842861
$8,244.78
in general payments reported to CMS, 2019-2025
40 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,701 · 2022: $1,684 · 2023: $1,648 · 2024: $1,575 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,843 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,843.30 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,549.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,486.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $789.49 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $590.51 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.41 | 2021-2025 | Tradjenta, Synjardy, Stiolto Respimat |
| Pfizer INC. | $472.17 | 2021-2025 | |
| Abbott Laboratories | $387.00 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $341.87 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $253.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $250.51 | 2022-2025 | |
| Glaxosmithkline, LLC. | $235.51 | 2022-2025 | Arexvy, Bexsero, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $161.97 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Esperion Therapeutics, INC. | $142.30 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $139.92 | 2021-2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $91.90 | 2021-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $77.43 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.38 | 2021-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $67.38 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $63.01 | 2022-2025 | Zoryve |
| Indivior INC. | $52.50 | 2024-2025 | Sublocade |
| Dexcom, INC. | $52.17 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $40.44 | 2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $37.76 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $36.94 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $33.47 | 2025 | Daybue |
| Novartis Pharmaceuticals Corporation | $28.44 | 2021-2023 | |
| Organogenesis INC. | $26.85 | 2022 | |
| Biogen, INC. | $26.60 | 2021-2022 | |
| Amarin Pharma, INC. | $25.72 | 2021-2022 | |
| Curonix LLC | $24.16 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Boston Scientific Corporation | $21.87 | 2023 | |
| Aimmune Therapeutics, INC. | $21.85 | 2025 | Zenpep |
| Alexion Pharmaceuticals, INC. | $17.41 | 2021 | |
| Almatica Pharma LLC | $17.22 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.74 | 2025 | Recorlev |
| Optinose US, INC. | $15.61 | 2021 | |
| Axonics, INC. | $15.50 | 2021 | |
| Depuy Synthes Sales INC. | $14.80 | 2025 | Orthovisc, Monovisc |
| Genentech USA, INC. | $14.09 | 2022 | |
| Eisai INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Lynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.